Wang Lirui

Publisher:基础医学Release time:2017-12-26Times of browsing:173

PI introduction

Lirui Wang, Professor, Ph.D supervisor. Lirui got her Ph.D degree of Pharmacology from Shanghai Institute of Materia Medica, Chinese Academy of Science in 2011. At the same year, she joined WuXi AppTec Company in Shanghai as the Senior Scientist. In 2012, she went to the University of California, San Diego, USA to receive her Postdoctoral Scholar training. In 2016, Lirui was awarded “Jiangsu Distinguished Professor” and she joined China Pharmaceutical University at the same year in September. Up to today, she has already published more than 10 papers in very well-known journals including Cell Host & MicrobeJournal of Clinical InvestigationNature CommunicationJournal of HepatologyHepatologyFASEB Journal and so on.Her Cell Host & Microbe paper received enormous attention from the scientific and lay press. It received a full-page review and summary in Nature Reviews Gastroenterology & Hepatology, and was covered by various radio stations and newspapers throughout the world such as The Economist published in London, UK. Nowadays, Lirui is served as the invited reviewer for journals such as Pharmacological ResearchLiver international, Digestive Diseases and Sciences, European Journal of Pharmacology, The American Journal of Chinese Medicine and Cellular Immunology.

Publications



  1. Wang L, FoutsDE, Stärkel P, Hartmann P, Chen P, Llorente C, DePew J, Moncera K, Ho SB, Brenner DA, HooperLV, Schnabl B.Intestinal REG3 lectins protect mice from alcohol-induced steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation. Cell Host & Microbe 2016 Feb 10;19(2):227-39. PMID: 26867181(IF= 14.95)


  1. Wang L, Hartmann P, Haimerl M, Bathena S., Sjöwall C, Almer S, Alnouti Y, Hofmann A, and Schnabl B. Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids.Journal of Hepatology. 2014 Jun;60(6):1259-67. PMID: 24560660 (IF=12.49)


  1. Mazagova M*, Wang L*, Anfora AT, Wissmueller M, Lesley SA, Miyamoto Y, Eckmann L, Dhungana S, Pathmasiri W, Sumner S, Westwater C, Brenner DA, Schnabl B. Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice.FASEB J. 2015 Mar;29(3):1043-55. *Contributed equally to this work. PMID: 25466902 (IF= 5.498)


  1. Wang L, Wang X, Chen J, Yang Z, Yu L, Hu L, and Shen X. Activation of Protein Serine/Threonine Phosphatase PP2Cα Efficiently Prevents Liver Fibrosis.PLoS ONE, 2010, 5(12): e14230. PMID:21151953 (IF=4.358)


  1. Wang L, Llorente C, Hartmann P, Yang A, Chen P, Schnabl B. Methods to determine intestinal permeability and bacterial translocation during liver disease.J Immunol Methods. 2015 Jun;421:44-53. PMID: 25595554(IF= 1.82)




  1.  Hartmann P, Seebauer CT, Mazagova M, Horvath A, Wang L, Llorente C, Varki NM, Brandl K, Ho SB, Schnabl B. Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity.Am J Physiol Gastrointest Liver Physiol. 2016 Mar 1;310(5):G310-22. PMID: 26702135 (IF=3.798)


  1. Inamine T, Yang AM, Wang L, Lee KC, Llorente C, Schnabl B. Immunoglobulin A deficiency does not affect development of alcoholic steatohepatitis in mice.Alcohol Clin Exp Res. 2016 (IF=2.8)



  1.  Hartmann P, Chen P, Wang HJ, Wang L, McCole DF, Brandl K, Stärkel P, Belzer C, Hellerbrand C, Tsukamoto H, Ho SB, Schnabl B. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice.Hepatology. 2013 Jul;58(1):108-19. PMID:23408358 (IF=13.25)



  1.  Han C, Wang L, Yu K, Chen L, Hu L, Chen K, Jiang H, Shen X. Biochemical characterization and inhibitor discovery of shikimate dehydrogenase from Helicobacter pylori.FEBS J. 2006 Oct; 273(20):4682-92. PMID:16972983 (IF=4.001)



2017

  1.  Yang AM, Inamine T, Hochrath K, Chen P, Wang L, Llorente C, Bluemel S, Hartmann P, Xu J, Koyama Y, Kisseleva T, Torralba MG, Moncera K, Beeri K, Chen CS, Freese K, Hellerbrand C, Lee SM, Hoffman HM, Mehal WZ, Garcia-Tsao G, Mutlu EA, Keshavarzian A, Brown GD, Ho SB, Bataller R, Stärkel P, Fouts DE, Schnabl B. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest. 2017 Jun 30;127(7):2829-2841.(IF= 12.78)



  1. Hartmann P, Hochrath K, Horvath A, Chen P, Seebauer CT, Llorente C, Wang L, Alnouti Y, Fouts DE, Stärkel P, Loomba R, Coulter S, Liddle C, Yu RT, Ling L, Rossi SJ, DePaoli AM, Downes M, Evans RM, Brenner DA, Schnabl B. Modulation of the intestinal bile acid-FXR-FGF15 axis improves alcoholic liver disease in mice.Hepatology. 2017 Nov 21. (IF= 13.25)

  2. Llorente C, Jepsen P, Inamine T, Wang L, Bluemel S, Wang HJ, Loomba R, Bajaj JS, Schubert ML, Sikaroodi M, Gillevet PM, Xu J, Kisseleva T, Ho SB, DePew J, Du X, Sørensen HT, Vilstrup H, Nelson KE, Brenner DA, Fouts DE, Schnabl B.  Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat Commun. 2017 Oct 16;8(1):837. (IF= 12.12)



Editorials


  1.  Alcohol Lowers Your (Intestinal) Inhibitions. Cell Host & Microbe 19, February 10, 2016. Previews

  2.  Mucosal microbes exacerbate experimental alcoholic steatohepatitis. Nature Reviews Gastroenterology & Hepatology | Published online 17 Feb 2016.

  3.  Alcohol and liver disease study. NBC7 news.

  4.  Bugs in the system | The Economist. Feb 13th 2016.

  5.  Alcohol also damages the liver by allowing bacteria to infiltrate. ScienceDaily. February 10, 2016.


Oral presentations in AASLD liver meeting


 2013Oral presentation at the American Association for the Study of Liver Diseases 64th Annual Meeting. Washington, DC.

Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids

 2014 Oral presentation at the American Association for the Study of Liver Diseases 65th Annual Meeting. Plenary Session. Boston, MA.

Commensal microbiota is hepatoprotective and suppresses liver fibrosis in mice

 2015 Oral presentation at the American Association for the Study of Liver Diseases 66th Annual Meeting. San Francisco, CA.

Antimicrobial proteins Reg3b and Reg3g protect mice from alcoholic liver disease by preventing bacterial translocation


Potential collaborations

We have always being endeavored to explore the pathogenesis and therapeutics of a variety of chronic liver diseases, including alcoholic liver disease (ALD), non-alcoholic steatohepatitis (NASH), liver fibrosis and cirrhosis. We have successfully established the mice models of alcohol-induced liver hepatitis, high-fat-diet induced NASH, CCl4 and Bile duct ligation (BDL)-induced liver fibrosis. We are good at isolating primary hepatocytes, stellate cells and Kupffer cells from the liver as well as drug evaluation based on these cells. We also have extensive experience in identifying novel targets and establishing the target-based high throughput screening platforms to discover the novel drugs against these liver diseases.

Contact

Lirui Wang,

Ph.D,

Professor.

#639 Longmian Avenue, Jiangning District, Nanjing,211198,P.R.China.

Tel:+86-18005149688; email:wanglirui@cpu.edu.cn